Determinants of mortality in patients with type 2 diabetes: a review
- PMID: 27068710
- DOI: 10.1007/s11154-016-9349-0
Determinants of mortality in patients with type 2 diabetes: a review
Abstract
We aimed to review and summarize the evidence from accomplished trials analyzing factors influencing mortality in patients with T2DM and to provide some recommendations for targets and treatment in the European region. The following databases were searched for relevant trials: PubMed and the Cochrane Library. Of 3.806 citations, 134 trials met our inclusion criteria.
Results: The reduction in lifetime for 65 + -years-old patients having less than 10 years T2DM amounts to 1.8 years. Having T2DM for more than 10 years lifetime will be reduced by 2.7 years. However, the lifetime shortening factor of T2DM will even be stronger for 40 + -years-old patients at onset. Males will lose 11.6 years of life and 18.6 QUALYs. T2DM among females will reduce life by 14 QUALYs by 22 years. From a statistical point of view, the highest mortality rate will occur in an over 55-years-old European smoking and non-compliant diabetic woman with alcohol abuse living in a rural area with a low level of education and a low socio-economic status. Furthermore, other co-morbidities such as cardiovascular diseases, gout, and depression affect mortality. Additionally, mortality will increase with a BMI over 35 and also with a BMI under 20-25. This refers to the obesity paradox indicating a higher mortality rate among normal weight patients with T2DM compared to overweight patients with T2DM. HbA1c-levels between 6.5 % and 7 % are associated with the lowest impact on mortality.
Keywords: Determinants; Life expectancy; Lifetime; Mortality; Survival; T2DM.
Similar articles
-
Inverse relation of body weight and weight change with mortality and morbidity in patients with type 2 diabetes and cardiovascular co-morbidity: an analysis of the PROactive study population.Int J Cardiol. 2012 Dec 15;162(1):20-6. doi: 10.1016/j.ijcard.2011.09.039. Epub 2011 Oct 29. Int J Cardiol. 2012. PMID: 22037349 Clinical Trial.
-
Obesity paradox: differential effects on cancer and noncancer mortality in patients with type 2 diabetes mellitus.Atherosclerosis. 2013 Jan;226(1):186-92. doi: 10.1016/j.atherosclerosis.2012.09.004. Epub 2012 Sep 21. Atherosclerosis. 2013. PMID: 23040832
-
Are women with type 2 diabetes mellitus more susceptible to cardiovascular complications following coronary angioplasty?: a meta-analysis.BMC Cardiovasc Disord. 2017 Jul 27;17(1):207. doi: 10.1186/s12872-017-0645-8. BMC Cardiovasc Disord. 2017. PMID: 28750607 Free PMC article. Review.
-
Reduced pre-hospital and in-hospital survival rates after out-of-hospital cardiac arrest of patients with type-2 diabetes mellitus: an observational prospective community-based study.Europace. 2015 May;17(5):753-60. doi: 10.1093/europace/euv014. Epub 2015 Mar 8. Europace. 2015. PMID: 25755289
-
Impact of weight gain on outcomes in type 2 diabetes.Curr Med Res Opin. 2011 Jul;27(7):1431-8. doi: 10.1185/03007995.2011.585396. Epub 2011 May 23. Curr Med Res Opin. 2011. PMID: 21599553 Review.
Cited by
-
Treatment Effect of Type 2 Diabetes Patients in Outpatient Department Based on Blockchain Electronic Mobile Medical App.J Healthc Eng. 2021 Mar 1;2021:6693810. doi: 10.1155/2021/6693810. eCollection 2021. J Healthc Eng. 2021. Retraction in: J Healthc Eng. 2023 Jun 21;2023:9858173. doi: 10.1155/2023/9858173. PMID: 33728034 Free PMC article. Retracted.
-
Health-related quality of life in populations with diabetes, prediabetes, and normal glycemic levels in Guangzhou, China: a cross-sectional study.Front Endocrinol (Lausanne). 2025 May 23;16:1518204. doi: 10.3389/fendo.2025.1518204. eCollection 2025. Front Endocrinol (Lausanne). 2025. PMID: 40487765 Free PMC article.
-
The mitochondrial antioxidant SS-31 increases SIRT1 levels and ameliorates inflammation, oxidative stress and leukocyte-endothelium interactions in type 2 diabetes.Sci Rep. 2018 Oct 26;8(1):15862. doi: 10.1038/s41598-018-34251-8. Sci Rep. 2018. PMID: 30367115 Free PMC article.
-
Evaluation of an oral small-molecule glucagon-like peptide-1 receptor agonist, lotiglipron, for type 2 diabetes and obesity: A dose-ranging, phase 2, randomized, placebo-controlled study.Diabetes Obes Metab. 2025 Jan;27(1):215-227. doi: 10.1111/dom.16005. Epub 2024 Oct 16. Diabetes Obes Metab. 2025. PMID: 39415344 Free PMC article. Clinical Trial.
-
Trends in Depression Among Hospitalized Patients with Type 2 Diabetes in Spain (2017-2023): A Population-Based Analysis with a Focus on Sex Differences and In-Hospital Outcomes.J Clin Med. 2025 Jun 1;14(11):3895. doi: 10.3390/jcm14113895. J Clin Med. 2025. PMID: 40507657 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous